Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
An announcement made by Agilent Technologies describes that the company has completed it's acquisition of Bio Tek instruments.
As Agilent Technologies, Inc. has announced complete acquisition of Biotek instruments, it has promised the expansion of Agilent's expertise and presence in the cell analysis. This acquisition upgrades the company's place in the growing and huge immuno-oncology and immunotherapy areas.
BioTek Instruments is a globally renowned company working on the design, manufacture and distribution of innovative life science instrumentation.
This acquisition will benifit the company in so many ways and in different areas as well. The presence of the company in biopharma, academia and research is going to witness expansion because customers also are keenly interested in understanding complex cellular interactions and environment. This collaboration will stand for Agilent to deliver a range of unique cell analysis workflows to feed customers with the competence to obtain deeper, more dependable insights across a variety of cell analysis applications.
"We're extremely pleased to add BioTek's tremendously talented employees and industry leading technologies to the Agilent team," said Mike McMullen, Agilent president and CEO. "The combination of our two companies and our collective offerings will help lead to a better understanding of cell function, behavior and interactions. This will enable researchers to more quickly achieve significant breakthroughs in solving the most complex health and science challenges."
In Agilent's fiscal year fourth quarter, it's expected that BioTek will contribute approximately $20 million to $25 million to Agilent revenues with no material impact on fourth quarter earnings per share (EPS).
